Early experimental tests have shown complete eradication of cancerous tumors in the implementation of CICD

Orange County, CA - August 30th 2017 -  Early experimental tests have shown complete eradication of cancerous tumors in the implementation of a method known as Caspase Independent Cell Death (CICD). Dr Stephen Tait, who led the University of Glasgow research team into CICD, said the new method "often led to complete tumor regression" and "may be a more effective way to treat cancer" than the current technique, apoptosis. CICD also carries the lowest risk of cancer recurrence.

Apoptosis is the most common cancer treatment consisting of chemotherapy, radiation, and newer immunotherapies. Apoptosis is a process that targets cancer cells triggered by normal body developments, usually as a defense mechanism during healing. This process also activates the release of proteins called caspases- protease enzymes that play essential roles in programmed cell death. This natural process tends to create minimal side effects, but this triggered cell death is “silent,” meaning no other bodily processes are triggered with it. The body relies on these other processes to fight off infection and provide bodily care while under apoptosis.

Due to the silent process, apoptosis can leave behind malignant cancer cells. These defects in treatment leave the body unarmed and susceptible to the metastasizing of tumors while becoming impervious to cancer drugs.

Early experimental tests have shown complete eradication of cancerous tumors in the implementation of CICD

Alternatively, CICD does not use apoptosis and therefore does not release caspases. CICD, while still triggering cell death, allows the body’s natural immune system to protect itself while under treatment destroying the remaining cancerous cells normally left behind. "Although many cancer treatments work by triggering apoptosis, that method sometimes fails to finish the job and instead may lead to the tumor becoming harder to treat,” said Dr. Justine Alford, senior science information officer for Cancer Research UK, the organization co-funding the study. "This new research suggests there could be a better way to kill cancer cells which, as an added bonus, also activates the immune system.”

While the research team in Glasgow used colorectal cancer cells in their study, they admit that the benefits of CICD could be used for a wider variety of cancer types. Dr. Tait is excited by this breakthrough, but knows there is much work left to be done. In his interview with Sky News he stated, "Taking into consideration our findings, we propose that engaging CICD as a means of anti-cancer therapy warrants further investigation."

Contact Ampronix:

Increasing Breastfeeding Rates

Email: info@ampronix.com 

International Sales: +1 949-273-8000

Domestic Sales: 1800-400-7972 for US and Canada

Follow Us:

FacebookTwitterLinkedIn

Share This Article:

TwitterFacebookLinkedIn

View our Product Catalog Online Here

 

About Ampronix

Ampronix is a renowned authorized master distributor of the medical industry's top brands as well as a world class manufacturer of innovative technology. Since 1982, Ampronix has been dedicated to meeting the growing needs of the medical community with its extensive product knowledge, outstanding service, and state-of-the-art repair facility. Ampronix prides itself on its ability to offer tailored, one-stop solutions at a faster and more cost effective rate than other manufacturers. Ampronix is an ISO & ANSI/ESD certified facility. To learn more go here.

Early experimental tests have shown complete eradication of cancerous tumors in the implementation of CICD Orange County, CA – August 30th 2017 –  Early experimental tests have shown complete eradication of cancerous tumors in the implementation of a method known as Caspase Independent Cell Death (CICD). Dr Stephen Tait, who led the University of Glasgow research […]